

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

5

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : C07D 477/00, C07F 9/568 C07D 409/14, 409/12 A61K 31/40		A1	(11) International Publication Number: WO 93/19070 (43) International Publication Date: 30 September 1993 (30.09.93)
(21) International Application Number: PCT/GB93/00603 (22) International Filing Date: 24 March 1993 (24.03.93) (30) Priority data: 92400836.0 26 March 1992 (26.03.92) EP (34) Countries for which the regional or international application was filed: FR et al. 92402763.4 9 October 1992 (09.10.92) EP (34) Countries for which the regional or international application was filed: FR et al.		(72) Inventor; and (75) Inventor/Applicant (for US only) : JUNG, Frédéric, Henri [FR/FR]; Rue du Moulin Cliquot-Taissy, F-51500 Rilly-la-Montagne (FR). (74) Agent: DENERLEY, Paul, Millington; ICI Group Patents Services Department, P.O. Box No. 6, Shire Park, Bessemer Road, Welwyn Garden City, Hertfordshire AL7 1HD (GB). (81) Designated States: AT, AU, BB, BG, BR, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(71) Applicants (for all designated States except US): ZENECA LIMITED [GB/GB]; Imperial Chemical House, 9 Millbank, London SW1P 3JF (GB). ZENECA Pharma S.A. [FR/FR]; "Le Galien", 1, rue des Chauffours, B.P. 127, F-95022 Cergy Cédex (FR).			
Published <i>With international search report.</i>			

(54) Title: CARBAPENEM DERIVATIVES AS ANTIBIOTICS AND INTERMEDIATES THEREOF



(57) Abstract

The present invention relates to carbapenems and provides a compound of formula (I) wherein: R¹ is 1-hydroxyethyl, 1-fluoroethyl or hydroxymethyl; R² is hydrogen or C₁₋₄alkyl; R³ is hydrogen or C₁₋₄alkyl; and the thienyl ring is optionally further substituted by one or two substituents selected from halo, cyano, C₁₋₄alkyl, nitro, hydroxy, carboxy, C₁₋₄alkoxy, trifluoromethyl, C₁₋₄alkoxycarbonyl, amino, C₁₋₄alkylamino, di-C₁₋₄alkylamino, sulfonic acid, C₁₋₄alkylS(O)_n (wherein n is 0-2), C₁₋₄alkanoylamino, C₁₋₄alkanoyl(N-C₁₋₄alkyl)amino, carbamoyl, C₁₋₄alkylcarbamoyl, di-C₁₋₄alkylcarbamoyl and N-C₁₋₄alkanesulfonamido; or by a tetramethylene group attached to adjacent carbon atoms on the thienyl ring; or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof. Processes for their preparation, intermediates in their preparation, their use as therapeutic agents and pharmaceutical compositions containing them are also described.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BC	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brasil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TC	Togo
DE	Germany	MC	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

Carbapenem derivatives as antibiotics and intermediates thereof


The present invention relates to carbapenems and in particular to such compounds containing a carboxy substituted thienyl group. This invention further relates to processes for their preparation, to intermediates in their preparation, to their use as therapeutic agents and to pharmaceutical compositions containing them. The compounds of this invention are antibiotics and can be used in the treatment of any disease that is conventionally treated with antibiotics for example in the treatment of bacterial infection in mammals including humans.

Carbapenems were first isolated from fermentation media in 1974 and were found to have broad spectrum antibacterial activity. Since this discovery substantial investigations have been made into new carbapenem derivatives and many hundreds of patents and scientific papers have been published.

The first, and so far the only, carbapenem to be commercially marketed is imipenem (N-formimidoyl thienamycin). This compound has a broad spectrum of antibacterial activity.


The present invention provides compounds with a broad spectrum of antibacterial activity including against both Gram positive and negative, aerobic and anaerobic bacteria. They exhibit good stability to beta-lactamases. In addition representative compounds of this invention exhibit favourable pharmacokinetics.

The carbapenem derivatives referred to herein are named in accordance with the generally accepted semi-systematic nomenclature:



Accordingly the present invention provides a compound of the formula (I)

- 2 -



(I)

wherein:

R^1 is 1-hydroxyethyl, 1-fluoroethyl or hydroxymethyl;

R^2 is hydrogen or C_{1-4} alkyl;

R^3 is hydrogen or C_{1-4} alkyl;

and the thienyl ring is optionally further substituted by one or two substituents selected from halo, cyano, C_{1-4} alkyl, nitro, hydroxy, carboxy, C_{1-4} alkoxy, trifluoromethyl, C_{1-4} alkoxy carbonyl, amino, C_{1-4} alkylamino, di- C_{1-4} alkylamino, sulfonic acid, C_{1-4} alkylS(0)_n- (wherein n is 0-2), C_{1-4} alkanoylamino, C_{1-4} alkanoyl($N-C_{1-4}$ alkyl)amino, carbamoyl, C_{1-4} alkylcarbamoyl, di- C_{1-4} alkylcarbamoyl and $N-C_{1-4}$ alkanesulfonamido; or by a tetramethylene group attached to adjacent carbon atoms on the thienyl ring; or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof.

The term alkyl includes all straight and branched chain structures, for example, C_{1-4} alkyl includes n-butyl and 2-methylpropyl.

Preferably R^1 is 1-hydroxyethyl.

R^2 is hydrogen or C_{1-4} alkyl for example methyl, ethyl, n-propyl, 1-methylethyl and n-butyl.

Preferably R^2 is hydrogen or methyl. In particular R^2 is methyl.

R^3 is hydrogen or C_{1-4} alkyl for example methyl, ethyl, n-propyl, 1-methylethyl and n-butyl.

Preferably R^3 is hydrogen or methyl. In particular R^3 is hydrogen.

Suitable substituents for the thienyl ring includ , for example:-

- 3 -

for halo:	fluoro, chloro, bromo and iodo;
for C_{1-4} alkyl:	methyl, ethyl, propyl, 1-methylethyl, butyl and 2-methylpropyl;
for C_{1-4} alkoxy:	methoxy, ethoxy, propoxy, 1-methylethoxy, butoxy and 2-methylpropoxy;
for C_{1-4} alkylcarbamoyl:	methylcarbamoyl, ethylcarbamoyl and propylcarbamoyl;
for di- C_{1-4} alkylcarbamoyl:	dimethylcarbamoyl and diethylcarbamoyl;
for C_{1-4} alkylamino:	methylamino, ethylamino and propylamino;
for di- C_{1-4} alkylamino:	dimethylamino, diethylamino and methylethylamino;
for C_{1-4} alkylS(O) _n ⁻ :	methylthio, methylsulphanyl and methylsulphonyl;
for C_{1-4} alkanoylamino:	acetamido and propionamido;
for C_{1-4} alkoxycarbonyl:	methoxycarbonyl, ethoxycarbonyl and propoxycarbonyl;
for C_{1-4} alkanoyl(<u>N</u> - C_{1-4} alkyl)amino:	<u>N</u> -methylacetamido and <u>N</u> -ethylacetamido;
for <u>N</u> - C_{1-4} alkanesulfonamido:	<u>N</u> -methanesulfonamido and <u>N</u> -ethanesulfonamido.


Preferably, when the thienyl ring is optionally substituted, the optional substituents are selected from halo, cyano, C_{1-4} alkyl, nitro, carboxy, hydroxy, C_{1-4} alkoxy, carbamoyl, amino, trifluoromethyl and tetramethylene.

Most preferably, the thienyl ring is not further substituted or further substituted by one hydroxy, methyl or tetramethylene group.


The present invention covers all epimeric, diastereoisomeric and tautomeric forms of the compounds of the formula (I) wherein the absolute stereochemistry at the 5-position is as illustrated in formula (I). When a bond is represented as a wedge, this indicates that in three dimensions the bond would be coming forward out of the paper and when a bond is represented as hatched, this indicates that in three dimensions the bond would be going back into the paper. The compounds of the formula (I) have a number of other stereocentres, namely: within the group R^1 (when R^1 is 1-hydroxyethyl or 1-fluoroethyl); at the 6-position; at the 1-position (when R^2 is C_{1-4} alkyl); and at the 2' and

- 4 -

4' positions in the pyrrolidine ring:




Preferred compounds are those in which the beta-lactam protons are in trans configuration with respect to one another. When R¹ is 1-hydroxyethyl or 1-fluoroethyl it is preferred that the 8-substituent has the R-configuration. Thus a preferred class of compounds is that of the formula (III):



and pharmaceutically acceptable salts and in vivo hydrolysable esters thereof, wherein R², R³ and optional substituents on the thienyl ring are as hereinbefore defined.


When R² is C₁₋₄ alkyl, for example methyl, it is preferred that the compound is in the form of the 1R configuration.

Preferred compounds are those in which the pyrrolidine ring has the following absolute stereochemistry at the 2'- and 4'- positions:



- 5 -

A suitable class of compounds of the present invention is that of the formula (IV):



and pharmaceutically acceptable salts and in vivo hydrolysable esters thereof;

wherein R³ and optional substituents on the thienyl ring are as defined hereinbefore in formula (I).

In another aspect a suitable class of compounds are the compounds of the formula (IV) wherein R³ is hydrogen, methyl or ethyl; and optional substituents on the thienyl ring are as defined hereinabove in formula (I).

In yet another aspect a suitable class of compounds is that of the compounds of the formula (IV) wherein the thienyl ring is optionally further substituted by one or two substituents selected from methyl, ethyl, hydroxy, carboxy, cyano, fluoro, chloro, bromo, carbamoyl, nitro, methoxy, ethoxy and propoxy; or by a tetramethylene group attached to adjacent carbon atoms on the thienyl ring; and R³ is as defined hereinbefore in formula (I).

A particular class of compounds of the present invention is that of the formula (IV) wherein:

R³ is hydrogen or methyl;

and the thienyl ring is optionally further substituted by one substituent selected from methyl, ethyl, hydroxy, carboxy, cyano, chloro, bromo, nitro, methoxy, ethoxy and tetramethylene.

A preferred class of compounds of the present invention is that of the formula (IV) wherein:

R³ is hydrogen;

and the thienyl ring is optionally further substituted by one substituent selected from methyl, hydroxy, chloro, tetramethylene and carboxy.

- 6 -

A more preferred class of compounds of the present invention is that of the formula (IV) wherein:

R^3 is hydrogen;

and the thienyl ring is either not further substituted or substituted by one substituent selected from methyl or hydroxy or by tetramethylene.

Particular compounds of the present invention are, for example, the following compounds of the formula (IV):

(1R,5S,6S,8R,2'S,4'S)-2-(2-(2-carboxy-4-thienylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid;
(1R,5S,6S,8R,2'S,4'S)-2-(2-(2-carboxy-3-thienylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid;
(1R,5S,6S,8R,2'S,4'S)-2-(2-(4-carboxy-2-thienylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid;
(1R,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxy-2-(4,5,6,7)-tetrahydrobenzo[b]-thienylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid;
(1R,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxy-4-methyl-2-thienylcarbamoyl)-pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid;
(1R,5S,6S,8R,2'S,4'S)-2-(2-(2-carboxy-5-thienylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid;
(1R,5S,6S,8R,2'S,4'S)-2-(2-(5-carboxy-3-hydroxy-2-thienylcarbamoyl)-pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid;
and pharmaceutically acceptable salts and in vivo hydrolysable esters thereof.

Suitable pharmaceutically acceptable salts include acid addition salts such as hydrochloride, hydrobromide, citrate, maleate and salts formed with phosphoric and sulfuric acid. In another aspect suitable salts are base salts such as an alkali metal salt for example sodium or potassium, an alkaline earth metal salt for example calcium or magnesium, an organic amine salt for example triethylamine, morpholine, N-methylpiperidine, N-ethylpiperidine, procaine, dibenzylamine, N,N-dibenzylethylamine or aminoacids, for example. lysine.

- 7 -

For the avoidance of doubt there may be one, two, three or four salt-forming cations dependent on the number of carboxylic acid functions and valency of said cations.

Preferred pharmaceutically acceptable salts are sodium and potassium salts. However, to facilitate isolation of the salt during preparation, salts which are less soluble in the chosen solvent may be preferred, whether pharmaceutically acceptable or not.

In vivo hydrolysable esters are those pharmaceutically acceptable esters that hydrolyse in the human body to produce the parent hydroxy or carboxy compound. Such esters can be identified by administering, eg. intravenously to a test animal, the compound under test and subsequently examining the test animal's body fluids.

Suitable in vivo hydrolysable ester forming groups for hydroxy include acetyl, propionyl, pivaloyl, C_{1-4} alkoxy carbonyl for example ethoxycarbonyl and phenylacetyl. Suitable in vivo hydrolysable esters for carboxy include C_{1-6} alkoxy methyl esters for example methoxymethyl; C_{1-6} alkanoyloxy methyl esters for example pivaloyloxy methyl; C_{3-8} cycloalkoxy carbonyloxy C_{1-6} alkyl, for example 1-cyclohexyloxy carbonyloxyethyl; 1,3-dioxolen-2-onyl methyl esters for example 5-methyl-1,3-dioxolen-2-onyl methyl; phthalidyl esters and C_{1-6} alkoxy carbonyloxyethyl esters for example 1-methoxycarbonyloxyethyl and may be formed at any carboxy group in the compounds of this invention.

In order to use a compound of the formula (I) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof for the therapeutic treatment of mammals including humans, in particular in treating infection, it is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.

Therefore in another aspect the present invention provides a pharmaceutical composition which comprises a compound of the formula (I) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof and a pharmaceutically acceptable carrier.

The pharmaceutical compositions of this invention may be administered in standard manner for the disease condition that it is desired to treat, for example by oral, rectal or parenteral

administration. For these purposes the compounds of this invention may be formulated by means known in the art into the form of, for example, tablets, capsules, aqueous or oily solutions or suspensions, emulsions, dispersible powders, suppositories and sterile injectable aqueous or oily solutions or suspensions.

The compounds of the present invention may be formulated as dry powder filled vials, which may contain the compound of the present invention alone or as a dry blended mixture. For example an acidic compound of the present invention may be dry blended with an alkali metal carbonate or bicarbonate. Freeze dried formulations of compounds of the present invention, alone or as a mixture with standard excipients, are possible. Standard excipients include structure formers, cryoprotectants and pH modifiers, such as, mannitol, sorbitol, lactose, glucose, sodium chloride, dextran, sucrose, maltose, gelatin, bovine serum albumin (BSA), glycine, mannose, ribose, polyvinylpyrrolidine (PVP), cellulose derivatives, glutamine, inositol, potassium glutamate, erythritol, serine and other amino acids and buffer agents e.g. disodium hydrogen phosphate and potassium citrate.

In addition to the compounds of the present invention the pharmaceutical composition of this invention may also contain, or be co-administered with, one or more known drugs selected from other clinically useful antibacterial agents (for example other beta-lactams or aminoglycosides), inhibitors of beta-lactamase (for example clavulanic acid), renal tubular blocking agents (e.g. probenecid) and inhibitors of metabolising enzymes (for example inhibitors of dehydropeptidases, for example Z-2-acylamino-3-substituted propenoates such as cilastatin) and N-acylated amino acids such as betamipron (also see EP-A-178911).

A suitable pharmaceutical composition of this invention is one suitable for oral administration in unit dosage form, for example a tablet or capsule which contains between 100mg and 1g of the compound of this invention.

A preferred pharmaceutical composition of the invention is one suitable for intravenous, subcutaneous or intramuscular injection, for example a sterile injectable composition containing between 1 and 50% v/v of the compound of this invention.

- 9 -

Specific examples of compositions, which are constituted as a 1% solution in water, freeze dried and may be made up by adding 0.9% aqueous sodium chloride solution to give the required concentration, preferably 1mg-10mg/ml, are as follows:

Composition 1

Compound of Example 1 50mg

Composition 2

Compound of Example 1 50mg
Glycine 31mg


Further specific examples of compositions are as above, but where the compound of example 1 is replaced by any one of examples 2 to 7.

The pharmaceutical compositions of the invention will normally be administered to man in order to combat infections caused by bacteria, in the same general manner as that employed for imipenem due allowance being made in terms of dose levels for the pharmacokinetics of the compound of the present invention relative to the clinical use of imipenem. Thus each patient will receive a daily intravenous, subcutaneous or intramuscular dose of 0.05 to 5g, and preferably 0.1 to 2.5g, of the compound of this invention, the composition being administered 1 to 4 times per day, preferably 1 or 2 times a day. The intravenous, subcutaneous and intramuscular dose may be given by means of a bolus injection. Alternatively the intravenous dose may be given by continuous infusion over a period of time. Alternatively each patient will receive a daily oral dose which is approximately equivalent to the daily parenteral dose. Thus a suitable daily oral dose is 0.05 to 5g. of the compound of this invention, the composition being administered 1 to 4 times per day.

In a further aspect the present invention provides a process for preparing the compounds of the formula (I) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof which process

- 10 -

comprises deprotecting a compound of the formula (V) wherein the thienyl ring is optionally further substituted as in formula (I):



wherein R^2 is as hereinbefore defined; R^{10} is a group R^3 or an amino protecting group; R^{13} is a group R^1 , protected hydroxymethyl or 1-(protected hydroxy)ethyl; R^{11} is hydrogen or a carboxy protecting group; R^{12} is hydrogen or an amino protecting group, R^{18} is carboxy or a protected carboxy group and wherein any optional substituent on the thienyl ring is optionally protected; and wherein at least one protecting group is present; and thereinafter if necessary;

- (i) forming a pharmaceutically acceptable salt,
- (ii) esterifying to form an in vivo hydrolysable ester.

Protecting groups may in general be chosen from any of the groups described in the literature or known to the skilled chemist as appropriate for the protection of the group in question, and may be introduced by conventional methods.

Protecting groups may be removed by any convenient method as described in the literature or known to the skilled chemist as appropriate for the removal of the protecting group in question, such methods being chosen so as to effect removal of the protecting group with minimum disturbance of groups elsewhere in the molecule.

The compounds of the formula (V) are novel and form another aspect of the invention.

Specific examples of protecting groups are given below for the sake of convenience, in which "lower" signifies that the group to which it is applied preferably has 1-4 carbon atoms. It will be understood that these examples are not exhaustive. Where specific examples of methods for the removal of protecting groups are given

- 11 -

below these are similarly not exhaustive. The use of protecting groups and methods of deprotection not specifically mentioned is of course within the scope of the invention.

A carboxy protecting group may be the residue of an ester-forming aliphatic or araliphatic alcohol or of an ester-forming silanol (the said alcohol or silanol preferably containing 1-20 carbon atoms).

Examples of carboxy protecting groups include straight or branched chain (1-12C)alkyl groups (eg isopropyl, t-butyl); lower alkoxy lower alkyl groups (eg methoxymethyl, ethoxymethyl, isobutoxymethyl); lower aliphatic acyloxy lower alkyl groups, (eg acetoxymethyl, propionyloxymethyl, butyryloxymethyl, pivaloyloxymethyl); lower alkoxy carbonyloxy lower alkyl groups (eg 1-methoxycarbonyloxyethyl, 1-ethoxycarbonyloxyethyl); aryl lower alkyl groups (eg p-methoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, benzhydryl and phthalidyl); tri(lower alkyl)silyl groups (eg trimethylsilyl and t-butyldimethylsilyl); tri(lower alkyl)silyl lower alkyl groups (eg trimethylsilylethyl); diaryl(lower alkyl)silyl groups (eg t-butyl-diphenylsilyl); and (2-6C)alkenyl groups (eg allyl and vinyl ethyl).

Methods particularly appropriate for the removal of carboxyl protecting groups include for example acid-, base-, metal- or enzymically-catalysed hydrolysis, for groups such as p-nitrobenzyloxy-carbonyl, hydrogenation and for groups such as o-nitrobenzyloxy-carbonyl, photolytically.

Examples of hydroxy protecting groups include lower alkenyl groups (eg allyl); lower alkanoyl groups (eg acetyl); lower alkoxy carbonyl groups (eg t-butoxycarbonyl); lower alkenyloxycarbonyl groups (eg allyloxycarbonyl); aryl lower alkoxy carbonyl groups (eg benzyloxycarbonyl, p-methoxybenzyloxycarbonyl, o-nitrobenzyloxycarbonyl, p-nitrobenzyloxycarbonyl); tri lower alkylsilyl (eg trimethylsilyl, t-butyldimethylsilyl); diaryl(lower alkyl)silyl (eg t-butyldiphenylsilyl) and aryl lower alkyl (eg benzyl) groups.

Examples of amino protecting groups include formyl, aralkyl groups (eg benzyl and substituted benzyl, eg p-methoxybenzyl, nitrobenzyl and 2,4-dimethoxybenzyl, and triphenylmethyl);

- 12 -

di-*p*-anisylmethyl and furylmethyl groups; lower alkoxy carbonyl (eg *t*-butoxycarbonyl); lower alkenyloxycarbonyl (eg allyloxycarbonyl); aryl lower alkoxy carbonyl groups (eg benzyloxycarbonyl, *p*-methoxybenzyloxycarbonyl, *o*-nitrobenzyloxycarbonyl, *p*-nitrobenzyloxycarbonyl); trialkylsilyl (eg trimethylsilyl and *t*-butyldimethylsilyl); diaryl(lower alkyl)silyl (eg *t*-butyldiphenylsilyl); alkylidene (eg methylidene); benzylidene and substituted benzylidene groups.

Methods appropriate for removal of hydroxy and amino protecting groups include, for example, acid-, base-, metal- or enzymically-catalysed hydrolysis, for groups such as *p*-nitrobenzyloxycarbonyl, hydrogenation and for groups such as *o*-nitrobenzyloxycarbonyl, photolytically.



Preferred protecting groups for carboxy and hydroxy groups in compounds of the formula (I) are the groups allyl and *p*-nitrobenzyl. A preferred method for removal of the allyl group is by palladium catalysis using tetrakis(triphenylphosphine)palladium and Meldrum's acid, in DMF or a dipolar aprotic solvent tetrahydrofuran mixture, such as dimethylsulfoxide/tetrahydrofuran or 1,3-dimethyl-2-oxo-tetrahydro-pyrimidine/tetrahydrofuran, or an alcohol/tetrahydrofuran mixture such as isopropanol/tetrahydrofuran or ethanol/tetrahydrofuran, preferably at ambient temperature. Alternatively, methylaniline may be used in place of Meldrum's acid, in dichloromethane. These conditions allow isolation of the product by precipitation of the sodium salt on the addition of a sodium salt such as sodium 2-ethylhexanoate.

A preferred method for removal of the *p*-nitrobenzyl group is hydrogenation using a palladium catalyst.

In another aspect of the present invention the compounds of the formulae (I) and (V) may be prepared by


- a) reacting compounds of the formulae (VI) and (VII):

- 13 -



wherein R², R¹⁰, R¹¹, R¹², R¹³ and R¹⁸ are as hereinbefore defined, optional substituents on the thiaryl ring are as hereinbefore defined and L is a leaving group, or

b) cyclising a compound of the formula (VIII):



wherein R², R¹⁰, R¹¹, R¹², R¹³ and R¹⁸ are as hereinbefore defined, optional substituents on the thiaryl ring are as hereinbefore defined and R¹⁴, R¹⁵ and R¹⁶ are independently selected from C₁₋₆alkoxy, aryloxy, di-C₁₋₆alkylamino and diarylamino or any two of R¹⁴-R¹⁶ represent o-phenylenedioxy or one of R¹⁴-R¹⁶ is C₁₋₄alkyl, allyl, benzyl or phenyl, and the other two values are independently selected from C₁₋₄alkyl, trifluoromethyl or phenyl, wherein any phenyl group is optionally substituted with C₁₋₃alkyl or C₁₋₃alkoxy; and wherein any functional group is optionally protected and thereinafter if necessary:

- (i) removing any protecting groups;
- (ii) forming a pharmaceutically acceptable salt;
- (iii) esterifying to form an in vivo hydrolysable ester.

Suitably in the compound of the formula (VI), L is the reactive ester of a hydroxy group such as a sulfonate (for example C₁₋₆alkanesulfonyloxy, trifluoromethanesulfonyloxy, benzenesulfonyloxy, toluenesulfonyloxy), a phosphoric ester (for example a diarylphosphoric ester such as diphenylphosphoric ester) or L is a halide (for example chloride). In an alternative L is a sulfoxide

- 14 -

for example $-\text{SOCH}=\text{CH}-\text{NHCOCH}_3$ which may be readily displaced.


Preferably L is diphenylphosphoric ester ($-\text{OP(0)(OPh)}_2$).

Compounds of the formula (VI) and their preparation are well known in the carbapenem literature, for example see EP-A-126587, EP-A-160391, EP-A-243686 and EP-A-343499.

The reaction between the compounds of the formulae (VI) and (VII) is typically performed in the presence of a base such as an organic amine for example di-isopropylethylamine or an inorganic base for example an alkali metal carbonate such as potassium carbonate. The reaction is conveniently performed at a temperature between -25°C and ambient, suitably at about 4°C . The reaction is generally performed in an organic solvent such as acetonitrile or dimethylformamide. The reaction is generally performed in a manner similar to that described in the literature for similar reactions.

The compounds of the formula (VII) are novel and form another aspect of the present invention.

The compounds of the formula (VII) may be prepared by the deprotection of a compound of the formula (IX):




wherein R^{10} , R^{12} and R^{18} are as hereinbefore defined, optional substituents on the thiienyl ring are as hereinbefore defined and R^{17} is a protecting group, for example C_{1-6} alkanoyl, C_{1-6} alkoxy carbonyl or benzoyl. Preferred values for R^{17} are acetyl and t -butoxycarbonyl. The compounds of the formula (IX) can be converted to the compounds of the formula (VII) by standard methods of deprotection, for example acetyl groups can be removed by basic hydrolysis in aqueous alkanol, alkenol, for example allyl alcohol, or tetrahydrofuran.

The compounds of the formula (IX) are novel and form another aspect of the present invention.

- 15 -

The compounds of the formula (IX) may be prepared by the reaction of an activated derivative of a compound of the formula (X), which may be formed in situ, with a compound of the formula (XI):



wherein R^{10} , R^{12} , R^{17} and R^{18} are as hereinbefore defined and optional substitutents on the thiaryl ring are as hereinbefore defined.

Activated derivatives of the compound of the formula (X) include acid halides, anhydrides and 'activated' esters such as 1H-benzo[1,2,3]-triazol-1-yl, pentafluorophenyl and 2,4,5-trichlorophenyl esters or the benzimidazol-2-yl ester of the thiocarboxylic acid corresponding to (X). The reaction of the compounds of the formulae (X) and (XI) is performed under standard methods, for example in the presence of sulfonyl chloride at ambient temperature.

The compounds of the formulae (X) and (XI) are prepared by standard methods known to the skilled chemist such as the methods of the Examples hereinafter, the methods described in EP-A-126587 or by methods analogous or similar thereto.


Suitably, in the compounds of the formula (VIII), R^{14} , R^{15} and R^{16} are independently selected from C_{1-6} alkoxy such as methoxy, ethoxy, isopropoxy, n-propoxy or n-butoxy; aryloxy such as optionally substituted phenoxy; di- C_{1-6} alkylamino such as dimethylamino or diethylamino; diarylamino such as diphenylamino or any two of R^{14} - R^{16} represent \underline{o} -phenylenedioxy. Preferably each of R^{14} - R^{16} have the same value and are C_{1-6} alkoxy for example methoxy, ethoxy, isopropoxy or n-butoxy or are phenoxy.

The compounds of the formula (VIII) are cyclized under conventional conditions known in the art to form compounds of the formula (V). Typical conditions are heating in a substantially inert organic solvent such as toluene, xylene or ethyl acetate at temperatures in the region 60-150°C. Typically the reaction is

- 16 -

performed in an atmosphere of nitrogen and is carried out in the presence of a radical scavenger for example hydroquinone.


The compounds of the formula (VIII) may be formed and cyclized *in situ*. The compounds of the formula (VIII) may conveniently be prepared by reacting compounds of the formulae (XII) and (XIII):



wherein R^2 , $R^{10}-R^{16}$ and R^{18} are as hereinbefore defined and optional substituents on the thiophenyl ring are as hereinbefore defined. Suitably the compound of the formula (XIII) is a phosphite or is the functional equivalent of such a compound.

The reaction between the compounds of the formulae (XII) and (XIII) is conveniently performed in an organic solvent such as toluene, xylene, ethyl acetate, chloroform, dichloromethane, acetonitrile or dimethylformamide. Typically the reaction is carried out at an elevated temperature for example 60-150°C.

The compounds of the formula (XII) may be prepared by a number of methods known in the art. For example the compounds of the formula (XII) may be prepared by the acylation of a compound of the formula (XIV):




- 17 -

wherein R^2 , R^{10} , R^{12} , R^{13} , and R^{18} are as hereinbefore defined and optional substituents on the thiienyl ring are as hereinbefore defined with a compound of the formula (XV):



wherein R^{11} is as hereinbefore defined.

The compounds of the formula (XIV) may be prepared by reacting compounds of the formulae (XVI) and (VII):



wherein R^2 and R^{13} are as hereinbefore defined. The compounds of the formula (XVI) are known in the art and may be reacted with the compounds of the formula (VII) under conventional acylation methods known in the art.

Compounds of the formulae (VII), (XII) and (XIV) are novel and, as such, form another aspect of this invention.

The following biological test methods, data and Examples serve to illustrate the present invention.

Antibacterial Activity

The pharmaceutically acceptable carbapenem compounds of the present invention are useful antibacterial agents having a broad spectrum of activity in vitro against standard laboratory microorganisms, both Gram-negative and Gram-positive, which are used to screen for activity against pathogenic bacteria. The antibacterial spectrum and potency of a particular compound may be determined in a standard test system. In particular the carbapenems of the present invention show good stability to beta-lactamases and have a particularly good elimination half life in mammals. In general compounds show significant improvement over imipenem.

The antibacterial properties of the compounds of the invention may also be demonstrated in vivo in conventional tests.

Carbapenem compounds have generally been found to be relatively non-toxic to warm-blooded animals, and this generalisation holds true for the compounds of the present invention. Compounds representative of the present invention were administered to mice at doses in excess of those required to afford protection against bacterial infections, and no overt toxic symptoms or side effects attributable to the administered compounds were noted.

The following results were obtained for representative compounds on a standard in vitro test system using Diagnostic Sensitivity Test. The antibacterial activity is described in terms of the minimum inhibitory concentration (MIC) determined by the agar-dilution technique with an inoculum size of 10^4 CFU/spot.

- 19 -

ORGANISM	MIC (µg/ml)
	EXAMPLE 1
<i>S. aureus</i>	0.125
Oxford	
<i>E. coli</i>	0.008
DCO	
<i>P. morganii</i>	0.008
I + 001	
<i>Enterobacter</i>	0.008
<i>cloacae</i> P99-	
<i>B. fragilis</i>	0.125
AMP S	

In the following examples, which are representative of the scope:

- (a) NMR spectra were taken at 200MHz or 400MHz unless otherwise stated;
- (b) Allyloxy means the propen-1-yloxy group $-OCH_2CH=CH_2$;
- (c) THF means tetrahydrofuran;
- (d) DMF means dimethylformamide;
- (e) DMSO means dimethylsulphoxide;
- (f) Evaporation of solvents was carried out under reduced pressure;
- (g) HPLC means high pressure liquid chromatography;
- (h) Temperatures are in degrees centigrade.
- (i) TFA means trifluoroacetic acid; and
- (j) tlc means thin layer chromatography.

- 20 -

Example 1

(1R,5S,6S,8R,2'S,4'S)-2-(2-Carboxy-4-thienylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid (dipotassium salt).

A solution of 4-nitrobenzyl (1R,5S,6S,8R,2'S,4'S)-2-(1-(4-nitrobenzylloxycarbonyl)-2-(2-carboxy-4-thienylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylate (diisopropylethylamine salt) (equivalent to 250 mg of free acid, 0.31 mM) in water (10 ml) and potassium bicarbonate (65 mg, 0.629 mM) was hydrogenated at atmospheric pressure in the presence of palladium/carbon (10%) (200 mg). The reaction was followed by analytical HPLC. At the end of the reaction the catalyst was removed by filtration, and the residual solution purified by preparative HPLC (Nucleosil C-18, 10 μ M, diameter 2.4 cm; length 25 cm). Using water as the eluant the fractions containing the required compound were concentrated and lyophilised to give the title compound (65 mg, 37%). NMR (DMSO-d₆+ AcOD-d₄): δ 1.15 (2d, 2H); 1.75 (m, 1H); 2.65 (m, 1H); 2.82 (m, 1H); 3.2 (dd, 1H); 3.3-3.5 (m, 2H); 3.65 (m, 1H); 3.85-4.05 (m, 2H); 4.15 (dd, 1H); 7.72 (s, 1H); 7.78 (s, 1H).

The starting material was prepared as follows:

4-Nitro-2-thiophenecarboxylic acid

2-Thiophenecarboxylic acid (6.4 g, 50 mM) was suspended in acetic anhydride (15 ml) and fuming nitric acid (16 ml) in glacial acetic acid (25 ml) added slowly over 1 hour with stirring, while keeping the temperature of the reaction mixture below 30°C. The reaction mixture was stirred at ambient temperature for 2 hours. The product was purified by subjecting to chromatography (470 ml) on HP20SS resin using methanol/(water + 1% acetic acid): 0/100 \rightarrow 50/50 as eluant. The pure title compound was obtained (1.3 g) together with a mixture of 4- and 5- nitrothiophene-2-carboxylic acid (4.4 g).

NMR (CDCl₃): δ 8.35 (d, 1H); 8.5 (d, 1H).

- 21 -

4-Amino-2-thiophenecarboxylic acid

4-Nitro-2-thiophenecarboxylic acid (1 g, 5.7 mmol) was added with stirring to a solution of $\text{SnCl}_2 \cdot 2\text{H}_2\text{O}$ (3.25 g, 14.4 mmol) in concentrated HCl (10 ml). The mixture was stirred for 6 hours at ambient temperature and purified by subjecting to chromatography on HP20SS resin, using water as eluant, to give the title compound (0.59 g, 71 %).

NMR (DMSO-d₆+ AcOD-d₄): δ 7.6 (s, 2H).

(2S,4S)-1-(4-Nitrobenzylcarbonyl)-2-(2-carboxy-4-thienylcarbamoyl)-pyrrolidin-4-ylthioacetate.

(2S,4S)-4-Acetylthio-2-carboxy-1-(4-nitrobenzyloxycarbonyl)-pyrrolidine (1.5 g, 4.08 mmol) was dissolved at ambient temperature in thionyl chloride (10 ml). The mixture was stirred for 4 hours at ambient temperature. The thionyl chloride was evaporated, the residual oil taken up in dichloromethane/toluene (10 ml, 1:1) and the solvent removed by evaporation. The residual oil was dried under vacuum for 1 hour and dissolved in dichloromethane (25 ml). This solution was added to a mixture of 4-amino-2-thiophenecarboxylic acid (0.58 g, 4.08 mmol), trimethylsilyl chloride (1 ml, 8.2 mmol) and diisopropylethylamine (3 ml, 17.25 mmol) in dichloromethane (40 ml) at 0°. The reaction mixture was stirred for 12 hours at ambient temperature, the solvent evaporated and the residue dissolved in DMF and subjected to chromatography on HP20SS resin, eluting with acetonitrile/water/acetic acid (40:60:1), followed by concentration and lyophilisation to give the title compound (0.84 g, 42%).

NMR (DMSO-d₆+ AcOD-d₄): δ 1.92 (m, 1H), 2.32 (s, 3H), 2.76 (m, 1H), 3.35 (m, 1H); 3.9-4.2 (m, 2H); 4.42 (m, 1H); 5.0-5.35 (m, 2H); 7.45 (d, 1H); 7.65 (d, 1H); 7.76 (s, 2H); 7.96 (d, 1H); 8.22 (d, 1H).

(2S,4S)-1-(4-Nitrobenzyloxycarbonyl)-2-(2-carboxy-4-thienylcarbamoyl)-pyrrolidin-4-ylthiol.

(2S,4S)-1-(4-Nitrobenzyloxycarbonyl-2-(2-carboxy-4-thienylcarbamoyl)pyrrolidin-4-ylthioacetate (0.475 g, 0.963 mmol) was dissolved in a mixture of dioxane/water (1:1) (20 ml) and treated with a 1M aqueous solution of NaOH (2.5 ml, 2.4 mmol). The reaction was

- 22 -

monitored by HPLC. After 1 hour, the pH was adjusted to pH3 with a 6M aqueous solution of HCl, at 0°. The reaction mixture then was evaporated and dried under vacuum for 1 hour.

4-Nitrobenzyl (1R,5R,6S,8R,2'S,4'S)-2-(1-(4-nitrobenzyloxycarbonyl)-2-(2-carboxy-4-thienylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylate (diisopropylethylamine salt)

A solution of 4-nitrobenzyl (1R,5R,6S,8R)-6-(1-hydroxyethyl)-1-methyl-2-diphenylphosphoryloxycarbapenem-3-carboxylate (0.575 g, 0.968 mmol) in DMF (5 ml) was added to a solution of (2S,4S)-1-(4-nitrobenzyloxycarbonyl)-2-(2-carboxy-4-thienylcarbamoyl)pyrrolidin-4-ylthiol in DMF (5 ml). Diisopropylethylamine (0.505 ml, 2.9 mmol), tri-n-butylphosphine (0.24 ml, 0.968 mmol) and water (20 μ l, 0.968 mmol) were added to the reaction mixture, which was stirred at 4°C for 14 hours. The title compound was purified by subjecting to chromatography on HP20SS resin (100 ml) using acetonitrile/water (30:70) as the eluant. Evaporation and lyophilisation gave the title compound (0.375 g, 49%).

NMR (DMSO-d₆+ AcOD-d₄): δ 1.15 (t, 15H); 1.25 (2d, 6H); 1.95 (m, 1H); 2.81 (m, 1H); 3.15 (q, 2H); 3.3 (m, 1H); 3.42 (m, 1H); 3.5-3.7 (m, 3H); 3.9-4.2 (m, 3H); 4.2-4.35 (m, 1H); 4.35-4.55 (m, 1H); 5.15-5.45 (m, 4H); 7.35-8.05 (m, 8H); 8.15 (s, 1H); 8.18 (s, 1H).

Example 2

(1R,5S,6S,8R,2'S,4'S)-2-(2-Carboxy-3-thienylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid (dipotassium salt).

A solution of allyl (1R,5S,6S,8R,2'S,4'S)-2-(1-(4-nitrobenzyloxycarbonyl)-2-(2-carboxy-3-thienylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylate diisopropylethylamine salt (equivalent to 0.49 g of the free acid, 0.7 mmol) in THF (25 ml) was treated with triphenylphosphine (20 mg, 0.076 mmol), potassium hexanoate (0.46 M solution in ethyl acetate, 3.2 ml, 1.47 mmol), hexanoic acid (0.235 ml, 1.47 mmol) and tetrakis(triphenylphosphine)palladium (70 mg) for 1 hour at ambient

- 23 -

temperature. Ethyl acetate (25 ml) was then added to the reaction mixture and the precipitate collected by filtration. The precipitate was washed with ethyl acetate and dried (0.45 g, 87%). This crude product was dissolved in water (10 ml) and hydrogenated at atmospheric pressure over palladium/carbon (10%, 0.35 g). The deprotection was followed by analytical HPLC. At the end of the reaction (usually 0.5 to 1 hour), the catalyst was filtered off, and the filtrate concentrated and purified by subjecting to preparative chromatography (Nucleosil C-18), using water as the eluant, to give the title compound, after concentration and lyophilisation of the required fractions (0.13 g, 38%).

NMR (DMSO-d₆+ AcOD-d₄): δ 1.15 (2d, 6H); 1.75 (m, 1H); 2.5-2.7 (m, 2H); 3.18 (dd, 1H); 3.2-3.65 (m, 3H); 3.9-4.05 (m, 2H); 4.15 (dd, 1H); 7.55 (d, 1H); 7.98 (d, 1H).

(2S,4S)-1-(4-Nitrobenzylloxycarbonyl)-2-(2-carboxy-3-thienylcarbamoyl)-pyrrolidin-4-ylthioacetate.

The title compound was prepared from 3-nitro-2-thiophene-carboxylic acid using a similar method to that of example 1, except no silylation was necessary. The amino acid was solubilized in dichloromethane with diisopropylethyl amine.

NMR (DMSO-d₆+ AcOD-d₄, TFA-d): δ 2.15 (m, 1H); 2.27 (s, 3H); 2.85 (m, 1H); 3.4 (m, 1H); 3.85-4.3 (m, 2H); 4.53 (dd, 1H); 5.22 (d, 2H); 7.5 (d, 2H), 7.75 (d, 1H); 7.92 (d, 1H); 8.05 (d, 2H).

Allyl (1R,5S,6S,8R,2'S,4'S)-2-(1-(4-nitrobenzylloxycarbonyl)-2-(2-carboxy-3-thienylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylate (diisopropylethylamine salt).

The title compound was prepared from (2S,4S)-1-(4-nitrobenzylcarbonyl)-2-(2-carboxy-3-thienylcarbamoyl)pyrrolidin-4-ythiol and allyl (1R,5R,6S,8R)-6-(1-hydroxyethyl)-1-methyl-2-diphenyl-phosphoryloxycarbapenem-3-carboxylate using a similar method to that of example 1.

NMR (DMSO-d₆+ AcOD-d₄): δ 1.15 (s, 15H); 1.3 (2d, 6H); 2.05 (m, 1H); 2.88 (m, 1H); 3.15 (q, 2H); 3.25 (dd, 1H); 3.32-3.58 (m, 2H); 3.62 (qi, 2H); 3.9-4.05 (m, 2H); 4.05-4.3 (m, 2H); 4.4-4.65 (m, 3H); 5.0-5.4 (m,

- 24 -

4H); 5.85 (m, 1H); 7.45 (d, 1H); 7.64 (d, 1H), 7.7 (d, 1H); 7.85-8.02 (m, 2H); 8.25 (d, 1H).

Example 3

(1R,5S,6S,8R,2'S,4'S)-2-(2-(4-Carboxy-2-thienylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid (dipotassium salt).

The title compound was prepared from allyl (1R,5S,6S,8R,2'S,4'S)-2-(1-(4-nitrobenzyloxycarbonyl)-2-(4-allyloxycarbonyl-2-thienylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylate diisopropylethylamine salt using a similar method to that of example 2.

NMR (DMSO-d₆+ AcOD-d₄): δ 1.16 (2xd, 6H); 1.67 (m, 1H); 2.55 (m, 1H); 2.64 (m, 1H); 3.2 (dd, 1H); 3.39-3.43 (m, 2H); 3.60 (m, 1H); 3.93-3.97 (m, 2H); 4.15 (dd, 1H); 7.15 (s, 1H); 7.67 (s, 1H).

Allyl 2-nitro-4-thiophenecarboxylate

2-Nitro-4-thiophenecarboxylic acid (2.5 g, 14.45 mmol) was suspended in DMF (25 ml) in the presence of potassium carbonate (4 g, 28.9 mmol) at ambient temperature. Allyl bromide (5 ml, 57.8 mmol) was added to this solution and the mixture stirred at ambient temperature overnight. The mixture was diluted with water and extracted with ethyl acetate. After concentration, the residue was purified by silica gel chromatography using ethyl acetate/petroleum ether as eluant (10:30) to give the title compound (2.45 g, 77%).

NMR (CDCl₃): δ 4.78 (m, 1H); 4.80 (m, 1H); 5.25 (m, 1H); 5.45 (d, 1H); 6.0 (m, 1H); 8.25 (d, 1H); 8.75 (d, 1H).

Allyl 2-amino-4-thiophenecarboxylate

Allyl 2-nitro-4-thiophenecarboxylate was suspended in concentrated HCl (25 ml), at 0°. SnCl₂.2H₂O (7.44 g, 32.36 mmol) was added and after stirring for 4 hours at ambient temperature the pH was adjusted to 10 with NaOH. Extraction with ethyl acetate and purification by subjecting to flash silica gel chromatography using ethyl acetate/petroleum ether as eluant (25:75), gave the title

- 25 -

compound (1.15 g, 55%).

NMR (CDCl₃): δ 3.75 (m, 2H); 4.65 (m, 1H); 4.72 (m, 1H); 5.2 (m, 1H); 5.35 (d, 1H); 6. (m, 1H); 6.57 (d, 1H); 7.35 (d, 1H).

(2S,4S)-1-(4-Nitrobenzyloxycarbonyl)-2-(4-allyloxycarbonyl-2-thienylcarbamoyl)pyrrolidin-4-ylthioacetate (diisopropylethylamine salt).

The title compound was prepared from allyl 2-amino-4-thiophenecarboxylate using a similar method to that of example 1, except allyl 2-amino-4-thiophenecarboxylate was solubilized in dichloromethane with diisopropylethylamine as described in example 2. NMR (DMSO-d₆): δ 1.9 (m, 1H); 2.35 (s, 3H); 2.75 (m, 1H); 3.25 (m, 1H); 3.85-4.25 (m, 2H); 4.5 (m, 1H); 4.65-4.85 (m, 2H); 5.05-5.5 (m, 4H); 6.0 (m, 1H), 6.9-8.4 (m, 6H).

Allyl (1R,5S,6S,8R,2'S,4'S)-2-(1-(4-nitrobenzyloxycarbonyl)-2-(4-allyloxycarbonyl-2-thienylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylate.

The title compound was prepared from (2S,4S)-1-(4-nitrobenzyloxycarbonyl)-2-(4-allyloxycarbonyl-2-thienylcarbamoyl)pyrrolidin-4-ylthio acetate using a similar method to that of example 2. NMR (DMSO-d₆+ AcOD-d₄): δ 1.15 (2d, 6H); 1.9 (m, 1H); 2.8 (m, 1H); 3.25 (dd, 1H); 3.35 (m, 1H); 3.55 (m, 1H); 3.9-4.05 (m, 2H); 4.2 (m, 1H); 4.4-4.75 (m, 5H); 5.0-5.4 (m, 6H); 5.8-6.1 (m, 1H); 7.4-8.3 (m, 6H).

Example 4

(1R,5S,6S,8R,2'S,4'S)-2-(2-(3-Carboxy-2-(4,5,6,7)-tetrahydrobenzo(b)-thienylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid (dipotassium salt).

The title compound was prepared from allyl (1R,5S,6S,8R,2'S,4'S)-2-(1-(4-nitrobenzyloxycarbonyl)-2-(3-carboxy-2-(4,5,6,7)-tetrahydrobenzo[b]thienylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylate diisopropylethylamine salt using a similar method to that of example 2.

NMR (DMSO-d₆+ AcOD-d₄): δ 1.15 (2d, 6H); 1.60-1.85 (m, 4H); 2.4-2.85

- 26 -

(m, 6H); 3.18 (dd, 1H); 3.3-3.65 (m, 3H); 3.88-4.1 (m, 2H); 4.15 (dd, 1H).

(2S,4S)-1-(4-Nitrobenzyloxycarbonyl)-2-(3-carboxy-2-(4,5,6,7)-tetrahydrobenzo[b]thienylcarbamoyl)pyrrolidin-4-ylthioacetate

The title compound was prepared from 2-amino-3-carboxy-4,5,6,7-tetrahydrobenzo[b]thiophene using a similar method to that of example 2.

NMR (DMSO-d₆+ AcOD-d₄): δ 1.62-1.82 (m, 4H); 2.15 (m, 1H); 2.5-2.9 (m, 5H); 3.45 (m, 1H); 3.95-4.25 (m, 2H); 4.6 (dd, 1H); 5.15 (d, 1H); 5.37 (d, 1H); 7.5 (d, 2H); 8.05 (d, 2H).

Allyl (1R,5S,6S,8R,2'S,4'S)-2-(1-(4-nitrobenzyloxycarbonyl)-2-(3-carboxy-2-(4,5,6,7)-tetrahydrobenzo[b]thienylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylate (diisopropylethylamine salt).

The title compound was prepared from allyl (1R,5R,6S,8R)-6-(1-hydroxyethyl)-1-methyl-2-diphenylphosphoryloxycarbapenem-3-carboxylate and (2S,4S)-1-(4-nitrobenzyloxycarbonyl)-2-(3-carboxy-2-(4,5,6,7)-tetrahydrobenzo[b]thienylcarbamoyl)pyrrolidin-4-ylthiol using a similar method to that of example 1.

NMR (DMSO-d₆+ AcOD-d₄): δ 1.15 (2d, 6H); 1.7 (s, 4H); 2.05 (m, 1H); 2.65 (s, 4H); 3.25 (dd, 1H); 3.3-4.75 (m, 10H); 4.9-5.45 (m, 4H); 5.75 (m, 1H); 7.1-8.35 (m, 4H).

Example 5

(1R,5S,6S,8R,2'S,4'S)-2-(2-(3-Carboxy-4-methyl-2-thienylcarbamoyl)-pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid (dipotassium salt).

The title compound was prepared from allyl (1R,5S,6S,8R,2'S,4'S)-2-(1-(4-nitrobenzyloxycarbonyl)-(2-(3-carboxy-4-methyl-2-thienylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem carboxylate diisopropylethylamine salt using a similar method to that of example 2.

NMR (DMSO-d₆+ AcOD d₄): 1.15 (2d, 6H); 1.7 (m, 1H); 2.32 (s, 3H); 2.52

- 27 -

(m, 1H); 2.67 (m, 1H); 3.18 (dd, 1H); 3.19 (m, 1H); 3.50 (m, 2H); 3.95 (m, 1H); 4.02 (m, 1H); 4.15 (dd, 1H); 6.55 (s, 1H).

(2S,4S)-1-(4-Nitrobenzyloxycarbonyl)-2-(3-ethoxycarbonyl-4-methyl-2-thienylcarbamoyl)pyrrolidin-4-ylthioacetate.

The title compound was prepared from ethyl 2-amino-4-methyl-3-thiophenecarboxylate using a similar method to that of example 2 except the ethyl 2-amino-4-methyl-3-thiophenecarboxylate was dissolved in dichloromethane in the presence of diisopropylethylamine.

NMR (CDCl_3): δ 1.35 (m, 3H); 2.2 (m, 1H); 2.35 (2s, 6H); 2.82 (m, 1H); 3.52 (m, 1H); 4.0 (m, 1H); 4.12-4.4 (m, 3H); 4.4-4.7 (m, 1H); 4.9-5.5 (m, 2H); 6.42 (s, 1H); 7.2-8.3 (m, 4H).

(2S,4S)-1-(4-Nitrobenzyloxycarbonyl)-2-(3-carboxy-4-methyl-2-thienylcarbamoyl)pyrrolidin-4-ylthiol

(2S,4S)-1-(4-Nitrobenzyloxycarbonyl)-2-(3-ethoxycarbonyl-4-methyl-2-thienylcarbamoyl)pyrrolidin-4-ylthioacetate (0.86 g, 1.6 mmol) in dioxan (10 ml) and water (5 ml) was treated with 1M NaOH (5ml, 4.8 mmol) for 3 hours at 60°. The reaction mixture was neutralised with 6M HCl to pH6, at 0°. The precipitated white solid was filtered off, washed with water and dried under vacuum.

Allyl (1R,5S,6S,8R,2'S,4'S)-2-(1-(4-nitrobenzyloxycarbonyl)-2-(3-carboxy-4-methyl-2-thienylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarabenem-3-carboxylate (diisopropylethylamine salt).

The title compound was prepared from allyl (1R,5R,6S,8R)-6-(1-hydroxyethyl)-1-methyl-2-diphenylphosphoryloxycarbabenem-3-carboxylate and (2S,4S)-1-(4-nitrobenzyloxycarbonyl)-2-(3-carboxy-4-methyl-2-thienylcarbamoyl)pyrrolidin-4-ylthiol using a similar method to that of example 1.

NMR ($\text{DMSO-d}_6 + \text{AcOD-d}_4$) 1.15 (m, 6H); 2.05 (m, 1H); 2.15 (m, 3H); 2.9 (m, 1H); 3.12 (dd, 1H); 3.4-3.6 (m, 2H); 3.9-4.15 (m, 2H); 4.42 (m, 2H); 4.6 (m, 3H); 5.0-5.4 (m, 4H); 5.6-6.05 (m, 1H); 6.62 (m, 1H); 7.2-8.3 (m, 4H).

Example 6

(1R,5S,6S,8R,2'S,4'S)-2-(2-Carboxy-5-thienylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid, dipotassium salt.

To a solution of 4-nitrobenzyl (1R,5S,6S,8R,2'S,4'S)-2-(1-(4-nitrobenzyloxycarbonyl)-2-(2-allyloxycarbonyl-5-thienylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylate (1 g, 1.2 mmol) in a mixture of methylene chloride (5 ml) and ethyl acetate (5 ml) were added triphenylphosphine (32 mg, 0.12 mmol), tetrakis triphenylphosphine palladium (48 mg, 0.04 mmol) and a 0.4M solution of potassium 2-ethyl hexanoate in ethyl acetate (3.5 ml, 1.38 mmol). The reaction mixture was stirred at ambient temperature for 1 hour, diluted with ethyl acetate and the precipitate filtered off, washed with ether and dried under vacuum. The crude acid was dissolved in a solution of water (30 ml) containing potassium hydrogen carbonate (132 mg, 1.32 mmol) and mixed with 10% palladium on charcoal (0.5 g). The mixture was stirred under a hydrogen atmosphere for 2 hours. The catalyst was filtered off, the organic phase discarded, the aqueous phase partially concentrated and purified by reverse phase chromatography (Nucleosil C₁₈ 10μ, 3.5 x 20 cm) with water as eluent to give after freeze drying the title compound (183 mg, 27%).

NMR (DMSO-d₆, AcOD-d₄): δ 1.15 (d, 3H); 1.17 (d, 3H); 1.75 (m, 1H); 2.63 (m, 1H); 2.76 (m, 1H); 3.20 (dd, 1H); 3.34-3.43 (m, 2H); 3.64 (m, 1H); 3.94-4.02 (m, 2H); 4.15 (dd, 1H); 6.87 (d, 1H); 7.49 (d, 1H).

MS (FAB + ve): 482 (M+H)⁺; 520 (M+K)⁺.

The starting materials were prepared as follows:

5-Nitro-2-thiophenecarboxylic acid.

The title compound was obtained starting from 2-thiophene-carboxylic acid, simultaneously with 4-nitro-2-thiophenecarboxylic acid described previously in example 1.

NMR (CDCl₃): δ 7.65 (d, 1H); 7.88 (d, 1H).

Allyl 5-Nitro-2-thiophenecarboxylate

To a solution of 5-nitro-2-thiophenecarboxylic acid (20 g, 0.11 mol) in DMF (140 ml) were added sequentially allyl bromide (40 ml, 0.46 mol) and triethylamine (64 ml, 0.46 mol) with cooling to maintain the temperature of the reaction mixture below 30°C. After addition of the reagents, the reaction mixture was stirred for 3 hours at ambient temperature and then diluted with ethyl acetate. The solid which precipitated was filtered off, the filtrate washed with water, washed with saturated aqueous solution of sodium chloride, dried over $MgSO_4$ and concentrated. The residue was purified by chromatography on silica gel using a mixture of CH_2Cl_2 - petroleum ether (3:7) as eluent to give the title compound as a white solid (8.8 g, 38%).

NMR ($CDCl_3$): δ 4.84 (d, 2H); 5.36-5.45 (m, 2H); 6.00 (m, 1H); 7.71 (d, 1H); 7.88 (d, 1H).

Allyl 5-amino-2-thiophenecarboxylate

To a solution of allyl 5-nitro-2-thiophenecarboxylate (3.2 g, 15 mmol) in concentrated hydrogen chloride (35 ml) was added, under cooling, $SnCl_2 \cdot H_2O$ (10.1 g, 45 mmol). The mixture was stirred for 3.5 hours at ambient temperature, diluted with ethyl acetate and basified to pH 10 with 5N NaOH. The organic layer was washed with water and a saturated aqueous solution of sodium chloride, dried over $MgSO_4$ and concentrated. The residue was purified by chromatography on silica gel using a mixture of ethyl acetate and petroleum ether (3:7) to give the title compound as a yellow oil (1.94 g, 72%).

NMR ($CDCl_3$): δ 4.34 (br s, 2H); 4.73 (d, 2H); 5.23 (d, 1H); 5.36 (d, 1H); 5.99 (m, 1H); 6.09 (d, 1H); 7.48 (d, 1H).

(2S,4S)-1-(4-Nitrobenzyloxycarbonyl)-2-(2-allyloxycarbonyl-5-thienyl-carbamoyl)pyrrolidine-4-ylthioacetate.

To a solution of (2S,4S)-4-acetylthio-2-carboxy-1-(4-nitrobenzyloxycarbonyl)pyrrolidine (3.79 g, 10.3 mmol) in CH_2Cl_2 (12 ml) were added thionyl chloride (3.75 ml, 51.5 mmol) and DMF (0.055 ml). The mixture was stirred for 16 hours at ambient temperature, concentrated and the residual oil taken up in CH_2Cl_2 -toluene and reevaporated. The residue was dried under vacuum and solubilised in

- 30 -

CH_2Cl_2 (25 ml). To this solution cooled to 0°C was added N-diisopropylethylamine (2.05 ml, 11.8 mmol) and a solution of allyl 5-amino-2-thiophenecarboxylate (1.9 g, 10.3 mmol). After 15 minutes at ambient temperature, the solvent was evaporated and the residue taken up in a mixture of water and ethyl acetate. The organic layer was dried over MgSO_4 and evaporated to dryness. The residue was purified by chromatography on silica gel using a mixture of CH_2Cl_2 -ether (9:1) to give the title compound as a yellow foam (4.68 g, 85%).

NMR (DMSO-d₆ + AcOD-d₄): δ 2.33 (s, 3H); 2.80 (m, 1H); 3.38 (m, 1H); 4.00-4.15 (m, 2H); 4.52 (m, 2H); 4.77 (d, 2H); 5.02-5.42 (m, 4H); 6.00 (m, 1H); 6.77 (m, 1H); 7.45 (m, 1H); 7.60-7.68 (m, 2H); 7.95 (m, 1H); 8.23 (m, 1H).

(2S,4S)-1-(4-Nitrobenzyloxycarbonyl)-2-(2-allyloxycarbonyl-5-thienylcarbamoyl)pyrrolidin-4-ylthiol.

To a solution of (2S,4S)-1-(4-nitrobenzyloxycarbonyl)-2-(2-allyloxycarbonyl-5-thienylcarbamoyl)pyrrolidin-4-ylthioacetate (1.06 g, 2 mmol) in dichloromethane (2 ml) was added at 0°C ethanol (4 ml) followed by a 5N solution of methylamine in ethanol (0.8 ml, 4 mmol). The reaction mixture was stirred at ambient temperature for 1.5 hours and acidified to pH 4 with 6N HCl. Ethyl acetate was added to the solution, the organic layer was washed with water and aqueous solution of sodium chloride, dried over MgSO_4 and evaporated to give the title compound as a yellow foam (0.96 g, 97%).

NMR (DMSO-d₆ - TFA): δ 1.87 (m, 1H); 2.73 (m, 1H); 3.29 (m, 1H); 3.44 (m, 1H); 4.01 (m, 1H); 4.42 (m, 1H); 4.72 (br s, 2H), 5.02-5.40 (m, 4H); 6.01 (m, 1H); 7.76 (m, 1H); 7.43 (d, 1H); 7.61-7.68 (m, 2H); 7.93 (d, 1H); 8.25 (d, 1H).

4-Nitrobenzyl (1R,5S,6S,8R,2'S,4'S)-2-(1-(4-nitrobenzyloxycarbonyl)-2-(2-allyloxycarbonyl-5-thienylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylate.

To a solution of 4-nitrobenzyl (1R,5S,6S,8R)-6-(1-hydroxyethyl)-1-methyl-2-diphenylphosphoryloxycarbapenem-3-carboxylate (940 mg, 1.9 mmol) in acetonitrile (10 ml) were added sequentially N-diisopropylethylamine (0.33 ml, 1.9 mmol), (2S,4S)-1-(4-nitro-

- 31 -

benzyloxycarbonyl)-2-(2-allyloxycarbonyl-5-thienylcarbamoyl)pyrrolidin-4-ylthio (1g, 1.9 mmol), in tri-n-butylphosphine (0.095 ml, 0.38 mmol) and water (0.03 ml). The reaction mixture was kept at 4°C overnight, evaporated to dryness and the residue was purified by chromatography on silica gel using a mixture of CH_2Cl_2 - CH_3CN (7:3) to give the title compound as a yellow foam (1.03 g, 72%).

NMR (DMSO-d₆-AcOD-d₄): δ 1.17 (d, 3H); 1.19 (d, 3H); 1.95 (m, 1H); 2.83 (m, 1H); 3.30-3.62 (m, 3H); 3.96-4.30 (m, 4H); 4.47-4.60 (dt, 1H); 4.73 (br s, 2H); 5.03-5.44 (m, 6H); 6.00 (m, 1H); 6.77 (dd, 1H); 7.44 (d, 1H); 7.61 (dd, 1H); 7.67 (d, 1H); 7.7 (d, 2H); 7.94 (d, 1H); 8.21 (d, 1H); 8.24 (d, 2H).

Example 7

(1R,5S,6S,8R,2'S,4'S)-2-(5-Carboxy-3-hydroxy-2-thienylcarbamoyl)-pyrrolidine-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid.

A solution of sodium (1R,5S,6S,8R,2'S,4'S)-2-(1-(4-nitrobenzyloxycarbonyl)-2-(5-carboxy-3-hydroxy-2-thienylcarbamoyl)-pyrrolidine-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylate (92 mg, 0.13 mmol) in water (5 ml) and sodium bicarbonate (pH adjusted to 7.5) was hydrogenated at atmospheric pressure in presence of Pd/C (10%) (45 mg). The reaction was followed by analytical HPLC and took about 45 minutes. The catalyst was filtered off and the aqueous solution concentrated, and purified by preparative HPLC (Nucleosil C-18), eluting with water. Freeze drying the appropriate fractions gave the title compound (30 mg, 42%).

NMR: (DMSO-d₆+AcOD-d₄): δ 1.15 (m, 6H); 1.7 (m, 1H); 2.65 (m, 2H); 3.2 (dd, 1H); 3.45 (m, 2H); 3.6 (m, 1H); 3.95 (dq, 1H); 4.05 (t, 1H); 4.15 (dd, 1H); 7.18 (s, 1H).

The starting material was prepared as follows:

tert-Butyl 3-tert-butoxy-2-ethyloxycarbonyl-5-thiophenecarboxylate

A solution of ethyl-3-hydroxy-5-carboxy-2-thiophene-carboxylate (25 g, 0.115 mmol) in dry (25 g, 0.115 mmol) in dry CH_2Cl_2

- 32 -

(200 ml) was treated, at ambient temperature, with diisopropyl-tert-butylisourea (175 ml) added dropwise. This caused an exotherm which heated the mixture to reflux. The reaction mixture was then stirred for 12 hours, the solid removed by filtration, and the CH_2Cl_2 evaporated. The residual oil was purified by subjecting to silica gel chromatography, eluting with petroleum ether: ether (90:10) to give a mixture of two products (28.5 g). These two products were separated by flash chromatography, eluting with CH_2Cl_2 : petroleum ether (1:1), to give title compound (12.6 g, 33%).

NMR: (DMSO-d_6): δ 1.29 (t, 3H); 1.36 (s, 9H); 1.53 (s, 9H); 4.25 (q, 2H); 7.41 (s, 1H).

tert-Butyl-3-tert-butoxy-2-carboxy-5-thiophenecarboxylate

A solution of tert-butyl-3-tert-butoxy-2-ethyloxycarbonyl-5-thiophenecarboxylate (11.5 g, 35 mmol) in dioxane with NaOH (2N) (34.5 ml, 70 mmol) was heated for 1.45 hours at 50°C . The mixture was cooled to 0°C , neutralized with HCl (2N), and the solvent evaporated. The residue was triturated with a concentrated aqueous solution of Na_2CO_3 (400 ml) and ether (200 ml). The aqueous phase was recovered, cooled to 0°C , acidified with HCl (5N) and extracted with ether. After drying, concentration of the ethereal phase, and purification by flash silica gel chromatography, the title compound was obtained (3.45 g). NMR: (CDCl_3): δ 1.55 (s, 9H); 1.58 (s, 9H); 7.5 (s, 1H).

tert-Butyl-2-azidocarbonyl-3-tert-butoxy-5-thiophenecarboxylate

A solution of tert-butyl-2-carboxy-3-tert-butoxy-5-thiophenecarboxylate (3g, 0.01 mmol) in dry acetone (100 ml) was treated, at 0°C , with triethylamine (1.7 ml, 0.012 mmol) added dropwise. The mixture was stirred for 15 minutes and ethyl chloroformate (1.25 ml, 0.013 mmol) added dropwise, at 0°C . After 30 minutes, sodium azide (1.1 g, 0.017 mmol) in water (5 ml) was slowly added, at 0°C . After 4 hours, stirring at ambient temperature, the reaction mixture was filtered and the solvent evaporated. The oily residue was dissolved in CH_2Cl_2 , and the solution washed (2x) with water, dried over MgSO_4 and the solvent evaporated to give title compound (3.25 g, 100%).

- 33 -

NMR: (DMSO-d₆): δ 1.50 (s, 9H); 1.60 (s, 9H); 7.45 (s, 1H).

tert-Butyl-2-allyloxycarbonylamino-3-tert-butoxy-5-thiophenecarboxylate

A solution of tert-butyl-2-azidocarbonyl-3-tert-butoxy-5-thiophenecarboxylate (1.5 g, 4.6 mmol) in allyl alcohol (0.5 ml, 7.3 mmol) and dry toluene (15 ml) was heated at 100° for 30 minutes, until evolution of nitrogen stopped. The mixture was evaporated, and the residue purified by subjecting to flash chromatography over silica gel, eluting with petroleum ether: ether (4:1) to give the title compound (1.64 g, 100%).

NMR: (CDCl₃): δ 1.28 (s, 9H); 1.49 (s, 9H); 4.66 (m, 2H); 5.25-5.37 (m, 2H); 6.0 (m, 1H); 7.25 (m, 1H).

tert-Butyl-2-amino-3-tert-butoxy-5-thiophenecarboxylate

A solution of tert-butyl-2-allyloxycarbonylamino-3-tert-butoxy-5-thiophenecarboxylate (1.64 g, 4.62 mmol) in anhydrous THF (50 ml) was treated with PPh₃ (240 mg, 0.923 mmol), dimedone (1.3 g, 9.23 mmol) and Pd(PPh₃)₄ (300 mg, 0.277 mmol). After 30 minutes, the solvent was evaporated, and the residue purified by flash silica-gel chromatography, eluting with petroleum ether: ether (80:20), to give the title compound (975 mg, 98%).

NMR: (DMSO-d₆): δ 1.24 (s, 9H); 1.45 (s, 9H); 6.0 (s, 2H); 7.08 (s, 1H).

(2S,4S)-1-(4-Nitrobenzyloxycarbonyl)-2-(3-tert-butoxy-5-tert-butyloxycarbonyl-2-thienylcarbamoyl)pyrrolidin-4-ylthioacetate.

(2S,4S)-1-(4-Nitrobenzyloxycarbonyl)-4-acetylthio-2-carboxy-pyrrolidine (1.5 g, 4 mmol) was solubilized in dry CH₂Cl₂ (15 ml) and treated with thionylchloride (1.5 ml, 20 mmol) and a catalytic amount of DMF (20 ml). The mixture was stirred for 12 hours at ambient temperature, the solvent evaporated, and the residual oil, dried under vacuum for 2 hours, solubilized in CH₂Cl₂ (15 ml) and added to a solution of tert-butyl-2-amino-3-tert-butoxy-5-thenoate (1.1 g, 4 mmol) in CH₂Cl₂ (15 ml) and diisopropylethylamine (0.85 ml, 4.9 mmol), at 0°C. The mixture was stirred for 30 minutes, the solvent evaporated, and the residue purified by flash silica gel chromatography, eluting

- 34 -

with petroleum ether: ether (20:80), to give the title compound (2.17 g, 85%).

NMR: (CDCl₃): δ 1.56 (s, 9H); 1.58 (s, 9H); 2.32 (s, 3H); 2.55 (m, 1H); 2.74 (m, 1H); 3.38 (m, 1H); 4.01 (m, 1H); 4.15 (m, 1H); 4.63 (m, 1H); 5.3 (m, 2H); 7.39 (s, 1H); 7.52 (m, 2H); 8.22 (m, 2H).

(2S,4S)-1-(4-Nitrobenzyloxycarbonyl)-2-(3-hydroxy-5-carboxy-2-thienylcarbamoyl)pyrrolidin-4-ylthiol.

(2S,4S)-1-(4-Nitrobenzyloxycarbonyl)-2-(3-tert-butoxy-5-tert-butyloxycarbonyl-2-thienylcarbamoyl)pyrrolidin-4-ylthioacetate (1g, 1.6 mmol) was solubilized in CH₂Cl₂ (2 ml) and dry ethanol (5 ml) and treated with a solution of methylamine (4.24 M) in ethanol (1.15 ml, 4.83 mmol). The progress of the reaction was monitored by tlc. After 1.5 hours, the mixture was evaporated, the residue solubilized in CH₂Cl₂ (5 ml) and treated with TFA (5 ml) for 1.5 hours, at ambient temperature. The solvent was evaporated and the residue triturated with ether to give title compound (1.1 g, 100%).

NMR: (DMSO-d₆): δ 1.8 (m, 1H); 2.7 (m, 1H); 3.4 (m, 1H); 4.00 (m, 2H); 4.62 (m, 1H); 5.00-5.26 (m, 2H); 7.16 (m, 1H), 7.45 (m, 1H), 7.65 (m, 1H); 7.94 (m, 1H); 8.23 (m, 1H).

Allyl (1R,5R,6S,8R,2'S,4'S)-2-(1-(4-nitrobenzyloxycarbonyl-2-(3-hydroxy-5-carboxy-2-thienylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylate.

A solution of allyl (1R,5R,6S,8R)-6-(1-hydroxyethyl)-1-methyl-2-diphenylphosphoryloxycarbapenem-3-carboxylate (800 mg, 1.6 mmol) in DMF (8 ml) under argon was treated with (2S,4S)-1-(4-nitrobenzyloxycarbonyl)-2-(3-hydroxy-5-carboxy-2-thienylcarbamoyl)-pyrrolidin-4-ylthiol (752 mg, 1.6 mmol), diisopropylethylamine (0.835 ml, 4.8 mmol), tributylphosphine (200 μl, 0.8 mmol) and water (15 ml, 0.8 mmol), for 12 hours at ambient temperature. The mixture was then purified by subjecting to chromatography on a HP20SS column, eluting with a gradient of acetonitrile, water to give title compound (286 mg, 25%).

NMR: (DMSO-d₆ + AcOD-d₄): δ 1.1-1.3 (m, 6H); 1.85 (m, 1H); 2.75 (m, 1H); 3.25 (dd, 1H); 3.3 (m, 1H); 3.5-3.7 (m, 1H); 3.7-4.3 (m, 4H); 4.5-4.8

- 35 -

(m, 3H); 4.9-5.5 (m, 4H); 5.9 (m, 1H); 7.17 (m, 1H); 7.46 (m, 1H); 7.66 (m, 1H); 7.96 (m, 1H); 8.73 (m, 1H).


(1R,5R,6S,8R,2'S,4'S)-2-(1-(4-Nitrobenzyloxycarbonyl)-2-(3-hydroxy-5-carboxy-2-thienylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid.

A solution of allyl (1R,5R,6S,8R,2'S,4'S)-2-(1-(4-nitrobenzyloxycarbonyl)-2-(3-hydroxy-5-carboxy-2-thienylcarbamoyl)-pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylate (240 mg, 0.335 mmol) in DMF (4 ml) under argon, was treated with $Pd(PPh_3)_4$ (30 mg, 0.026 mmol) and Meldrum's acid (48 mg, 0.335 mmol). The mixture was stirred for 1 hour, at ambient temperature. The solvent was evaporated, the residue solubilized in water, the pH adjusted to 7.5 with $NaHCO_3$ and the solution purified by C_{18} (Nucleosil) chromatography, eluting with water: CH_3CN (gradient) to give the title compound, (92 mg, 39%).

NMR: (DMSO-d₆+AcOD-d₄): 1.15 (m, 6H); 1.85 (m, 1H); 2.5 (m, 1H) (under DMSO); 2.77 (m, 1H); 3.19 (dd, 1H); 3.25-3.5 (m, 1H); 3.8-4.2 (m, 3H); 4.6 (m, 1H); 4.7 (m, 1H); 5.0-5.3 (m, 2H); 7.15 (s, 1H); 7.46 (m, 1H); 7.67 (m, 1H); 7.97 (m, 1H); 8.24 (m, 1H).

CLAIMS

1. A compound of the formula (I):



or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof;

wherein:

R^1 is 1-hydroxyethyl, 1-fluoroethyl or hydroxymethyl;

R^2 is hydrogen or C_{1-4} alkyl;

R^3 is hydrogen or C_{1-4} alkyl;

and the thienyl ring is optionally further substituted by one or two substituents selected from halo, cyano, C_{1-4} alkyl, nitro, hydroxy, carboxy, C_{1-4} alkoxy, trifluoromethyl, C_{1-4} alkoxy carbonyl, amino, C_{1-4} alkylamino, di- C_{1-4} alkylamino, sulfonic acid, C_{1-4} alkylS(0)_n- (wherein n is 0-2), C_{1-4} alkanoylamino, C_{1-4} alkanoyl($N-C_{1-4}$ alkyl)amino, carbamoyl, C_{1-4} alkylcarbamoyl, di- C_{1-4} alkylcarbamoyl and $N-C_{1-4}$ alkanesulfonamido; or by a tetramethylene group attached to adjacent carbon atoms on the thienyl ring.

2. A compound according to claim 1 wherein R^1 is 1-hydroxyethyl.


3. A compound according to either claim 1 or claim 2 wherein R^2 is hydrogen or methyl.

4. A compound according to either claim 1 or claim 2 wherein R^2 is methyl.

5. A compound according to any one of claims 1 to 4 wherein R^3 is hydrogen.

- 37 -

6. A compound according to any one of claims 1 to 4, of the formula (IV):



wherein R^3 and optional substituents on the thienyl ring are as defined in claim 1.

7. A compound according to claim 6 wherein the thienyl ring is optionally substituted by halo, cyano, C_{1-4} alkyl, nitro, carboxy, hydroxy, C_{1-4} alkoxy, carbamoyl, amino, trifluoromethyl or tetramethylene.

8. A compound according to either claim 6 or claim 7 wherein R^3 is hydrogen and the thienyl ring is either not further substituted or substituted by one substituent selected from methyl or hydroxy or by tetramethylene.

9. A compound according to claim 1 which is

(1R,5S,6S,8R,2'S,4'S)-2-(2-(2-carboxy-4-thienylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid;
 (1R,5S,6S,8R,2'S,4'S)-2-(2-(2-carboxy-3-thienylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid;
 (1R,5S,6S,8R,2'S,4'S)-2-(2-(4-carboxy-2-thienylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid;
 (1R,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxy-2-(4,5,6,7)-tetrahydrobenzo[b]-thienylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid;
 (1R,5S,6S,8R,2'S,4'S)-2-(2-(3-carboxy-4-methyl-2-thienylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-

carboxylic acid;

(1R,5S,6S,8R,2'S,4'S)-2-(2-(2-carboxy-5-thienylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid;


(1R,5S,6S,8R,2'S,4'S)-2-(2-(5-carboxy-3-hydroxy-2-thienylcarbamoyl)-pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid;

and pharmaceutically acceptable salts thereof.

10. A pharmaceutical composition which comprises a compound according to any one of claims 1 to 9 and a pharmaceutically acceptable carrier.

11. A method of treatment of an infection by administering an antibacterially effective amount of a compound of the formula (I) to a patient in need thereof.

12. A process for preparing a compound according to claim 1 which comprises deprotecting a compound of the formula (V):





wherein R² is as defined in claim 1; R¹⁰ is a group R³ (as defined in claim 1) or an amino protecting group; R¹³ is a group R¹ (as defined in claim 1), protected hydroxymethyl or 1-(protected hydroxy)ethyl; R¹¹ is hydrogen or a carboxy protecting group; R¹² is hydrogen or an amino protecting group, R¹⁸ is carboxy or a protected carboxy group and wherein any optional substituent on the thienyl ring is as defined in claim 1 and is optionally protected; and wherein at least one protecting group is present; and thereafter if necessary;

- (i) forming a pharmaceutically acceptable salt,
- (ii) esterifying to form an in vivo hydrolysable ester.

13. A compound of the formula (V) as defined in claim 12.


14. A process for preparing a compound according to claim 1 or a compound of the formula (V) as defined in claim 12 which comprises:

a) reacting compounds of the formulae (VI) and (VII):



wherein R², R¹⁰, R¹¹, R¹², R¹³ and R¹⁸ are as defined in claim 12, optional substituents on the thiienyl ring as as defined in claim 12 and L is a leaving group, or

b) cyclising a compound of the formula (VIII):



wherein R², R¹⁰, R¹¹, R¹², R¹³ and R¹⁸ are as defined in claim 12, optional substituents on the thiienyl ring are as defined in claim 12, and R¹⁴, R¹⁵ and R¹⁶ are independently selected from C₁₋₆ alkoxy, aryloxy, di-C₁₋₆ alkylamino and diarylamino or any two of R¹⁴-R¹⁶ represent o-phenylenedioxy or one of R¹⁴-R¹⁶ is C₁₋₄ alkyl, allyl, benzyl or phenyl, and the other two values are independently selected from C₁₋₄ alkyl, trifluor methyl or phenyl, wherein any phenyl group is optionally substituted with C₁₋₃ alkyl or C₁₋₃ alkoxy; and wherein any functional group is optionally protected and thereinafter if necessary:




- 40 -

- (i) removing any protecting groups;
- (ii) forming a pharmaceutically acceptable salt;
- (iii) esterifying to form an in vivo hydrolysable ester.

15. A compound of the formula (I), as defined in claim 1, in the form of a non-pharmaceutically acceptable salt.

16. A compound of the formula (VII) or (VIII) as defined in claim 14.

17. A compound of the formula (IX), (XII) or (XIV):



wherein R², R¹⁰-R¹³ and R¹⁸ are as defined in claim 12 and R¹⁷ is a protecting group.

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/GB 93/00603

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) According to International Patent Classification (IPC) or to both National Classification and IPC			
Int.C1. 5 C07D477/00; C07F9/568; C07D409/14; C07D409/12 A61K31/40			
II. FIELDS SEARCHED			
Classification System Minimum Documentation Searched ⁷ Classification Symbols			
Int.C1. 5 C07D ; C07F ; A61K			
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸			
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹			
Category ¹⁰ Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²		Relevant to Claim No. ¹³	
A	EP,A,0 126 587 (SUMITOMO CHEMICAL CO. LTD.) 28 November 1984 see claims -----	1-17	
P,A	WO,A,9 217 481 (IMPERIAL CHEMICAL INDUSTRIES PLC) 15 October 1992 see claims -----	1-17	
* Special categories of cited documents : ¹⁰ "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family			
IV. CERTIFICATION			
Date of the Actual Completion of the International Search 22 JUNE 1993		Date of Mailing of this International Search Report 30.06.93	
International Searching Authority EUROPEAN PATENT OFFICE		Signature of Authorized Officer CHOULY J.	

INTERNATIONAL SEARCH REPORT

international application No.

PCT/GB93/00603**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Although claim 11 is directed to a method of treatment of (diagnostic method practised on) the human/animal body the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.

GB 9300603
SA 71796

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 22/06/93

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0126587	28-11-84	JP-A- 60166683 JP-C- 1684436 JP-B- 3052466 JP-A- 59205379 JP-A- 60001186 JP-B- 4063076 JP-A- 60019787 JP-A- 60058987 JP-C- 1521360 JP-A- 60104088 JP-B- 63055514 US-A- 4933333 US-A- 4943569 US-A- 5122604 JP-A- 1079181 JP-B- 4066872	29-08-85 31-07-92 12-08-91 20-11-84 07-01-85 08-10-92 31-01-85 05-04-85 12-10-89 08-06-85 02-11-88 12-06-90 24-07-90 16-06-92 24-03-89 26-10-92
-----	-----	-----	-----
WO-A-9217481	15-10-92	AU-A- 1448292 CN-A- 1066657 EP-A- 0508682	02-11-92 02-12-92 14-10-92
-----	-----	-----	-----